|Day Low/High||2.45 / 2.53|
|52 Wk Low/High||1.92 / 5.47|
Last week was a busy one for the portfolio, as we made a number of trades and saw outsized gains in several positions.
We're reducing our position in Inovio Pharmaceuticals and raising our rating on Hudson Technologies.
We bought into some tech names last week as a rotation occurred in the sector.
New strategic position will guide product discovery and scientific collaborations
Former Chief Marketing Officer at Merck Also Brings Women's Health Management Expertise
For the second week in a row, we initiated a new position, this time in a security tech name.
Inovio continues to investigate pre-treatment biomarkers which could identify patients most likely to respond to treatment with VGX-3100, increasing absolute efficacy of the product
We initiated a new position for the portfolio during the shortened holiday trading week.
Investors in Inovio Pharmaceuticals Inc. saw new options begin trading this week, for the January 2018 expiration.
We exited three biotech/pharma positions and added to two other holdings during a busy week for the portfolio.
We exited two positions today following a tough week for small-cap stocks.
Inovio's cancer immunotherapies show antigen-specific T-cell stimulation in head and neck and other solid tumors
The Cambridge, Mass.based firm unveiled positive top-line results from a pair of Phase 3 studies of brexanolone in postpartum depression.
Earnings analysis on four stocks -- and we are increasing our ACRX position on this weakness.
Last week, we increased our holdings in one position and added 2 Bullpen names.
Phase 1b/2a clinical trial combines Regeneron's PD-1 inhibitor cemiplimab and Inovio's T cell activator INO-5401 in brain cancer
We used price declines to scale into several holdings as small-caps underperformed the overall market.
Legendary investor Warren Buffett advises to be fearful when others are greedy, and be greedy when others are fearful. One way we can try to measure the level of fear in a given stock is through a technical analysis indicator called the Relative Strength Index, or RSI, which measures momentum on a scale of zero to 100.
Investors in Inovio Pharmaceuticals Inc. saw new options begin trading this week, for the December 15th expiration.
This week brings earnings from 5 portfolio holdings as the market continues to shrug off potential negatives.
We took some profits and added a Bullpen name, among other moves, during a rough week for a few portfolio names.
Trial to evaluate Inovio's INO-5401 and Genentech's TECENTRIQ® in patients with metastatic bladder cancer
Sign up to get started or log in to see your watchlist.
Enter a symbol above to add it to your watchlist.
A confirmation email has been sent to the address provided during registration. Please click on the appropriate link to confirm your email address.